Methods of modulating the ox40 receptor to treat cancer
AssigneeBoard of Regents, The University of Texas System
InventorsYong-Jun Liu, Tomoki Ito
Life of this patent
Estimating the term…
Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsYong-Jun Liu, Tomoki Ito
Estimating the term…
Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. OX40L inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX40L modulates the generation and function of IL-10 producing Foxp3+ Treg immunosuppressive T cells and blocks Foxp3+ Treg function. Further, provided are high throughput methods for identifying compounds that can inhibit the immunosuppressive function of IL-10 producing Tr1 cells.
A method of treating cancer comprising the step of administering to a subject in need thereof a therapeutically effective amount of an antibody that modulates the activation of the OX40 receptor, wherein the immunosuppressive function of Tr1 cells and Foxp3+ T-reg cells is inhibited.
A method to treat B cell lymphoma comprising the step of administering to a subject in need thereof a therapeutically effective amount of OX40 ligand or other OX40 receptor agonist.
A high throughput screening method for compounds that modulate the OX40 receptor comprising the steps of:
Dependencies are inferred from the claim text.